our ability to obtain coverage and reimbursement for procedures performed using our products; our ability to scale our organizational culture; the impact of the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or manageme...
The literature indicates that the most effective policy approach to improve equity is to increase reimbursement rates for Medicaid-CHIP services.24,35-37 However, if state budget constraints make this strategy unfeasible, AMCs' propensity toward serving publicly insured patients may make them candidates...
AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, reported financial results for the first quarter March 31, 2023.
In 2023, Olympus Corporation acquired Taewoong Medical Co. Ltd., a Korean medical device manufacturer specializing in gastrointestinal (GI) metallic stents. This acquisition bolstered Olympus’s GI EndoTherapy product portfolio and improved its ability to provide comprehensive solutions for improved patien...
public funds. Considering that the reimbursement of medicinal products is financed by recourse to the funds of regional authorities, healthcare authorities of the 17 Autonomous Regions also participate in the committee of the MoH that assesses decisions on pricing and reimbursement of medicinal products...
Create a free Seeking Alpha account to access breaking news and valuable research tools »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Subscription Support: 1-347-509-6837 RSS Feed Sitemap Group Subscriptions Affiliate Program About Us Careers ...
our ability to develop, manufacture, obtain and maintain regulatory approvals for, market and sell, our products; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures p...
1. Sharma et al. 2023. “Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus–Related Neoplasia in the United States.” Journal of Health Economics and Outcomes Research10, no. 1 (M...
and growth and expansion of our operations, and the anticipated tax treatment of the merger; our ability to retain, attract and hire key personnel; potential adverse reactions or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger; ...
political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of sepiapterin for PKU; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain...